Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03754790 |
Recruitment Status :
Active, not recruiting
First Posted : November 27, 2018
Last Update Posted : December 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary Objective:
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
-
To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
- Bleeding episodes
- Spontaneous bleeding episodes
- Joint bleeding episodes
- To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hemophilia | Drug: Fitusiran | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 355 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX |
Actual Study Start Date : | January 9, 2019 |
Estimated Primary Completion Date : | December 18, 2026 |
Estimated Study Completion Date : | December 18, 2026 |

Arm | Intervention/treatment |
---|---|
Experimental: Fitusiran
Participants will be administered fitusiran as a subcutaneous injection once monthly or every other month for up to 48 months post initiation of modified IMP dose/frequency or until fitusiran becomes commercially available, whichever comes first.
|
Drug: Fitusiran
Pharmaceutical form:solution for injection Route of administration: subcutaneous |
- Number of participants with treatment emergent adverse events (TEAEs) [ Time Frame: from study baseline (day 1) up to maximum 88 months ]The number of participants experiencing any TEAEs, serious TEAEs, discontinuation due to TEAEs and death will be reported
- Annualized bleeding rate (ABR) [ Time Frame: from first ever dose of fitusiran (day 1) up to maximum 78 months ]Annualized bleeding rate (ABR) in the treatment period
- Annualized spontaneous bleeding rate [ Time Frame: from first ever dose of fitusiran (day 1) up to maximum 78 months ]Annualized spontaneous bleeding rate in the treatment period
- Annualized joint bleeding rate [ Time Frame: from first ever dose of fitusiran (day 1) up to maximum 78 months ]Annualized joint bleeding rate in the treatment period
- Changes in Haem-A-quality of life (QoL) score [ Time Frame: from first ever dose of fitusiran (day 1) up to maximum 78 months ]Change in Haem A QoL physical health score and total score in the treatment period (in participants ≥17 years of age) from first ever dose of fitusiran (day 1) to month 48

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion criteria :
- Participant must be at least 12 years of age inclusive, at the time of signing the informed consent
- Participants with severe hemophilia A or B who have completed a Phase 3 fitusiran clinical trial
- Male
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. In countries where legal age of majority is above 18 years, a specific ICF must also be signed by the participant's legally authorized representative
Exclusion criteria:
- Completion of a surgical procedure within 14 days prior to screening, or currently receiving additional factor concentrate or BPA infusion for postoperative hemostasis
- Current participation in immune tolerance induction treatment (ITI)
- Current use of factor concentrates or bypassing agents (BPAs) as regularly administered prophylaxis designed to prevent spontaneous bleeding episodes except for participants requiring factor concentrates or BPAs prophylaxis during the study dosing pause period
- Use of compounds other than factor concentrates or BPAs for hemophilia treatment
- Current or prior participation in a gene therapy trial
- Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >1.5 × upper limit of normal reference range (ULN) for patients who are naïve to fitusiran at study start; ALT and/or AST > 5 x ULN for patients who were in the fitusiran arm in the parent study
-
Additional exclusions for participants not currently participating in a fitusiran trial at the time of enrollment in the lower dose cohort:
- Clinically significant liver disease
- History of arterial or venous thromboembolism
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03754790

Study Director: | Clinical Sciences & Operations | Sanofi |
Responsible Party: | Genzyme, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT03754790 |
Other Study ID Numbers: |
LTE15174 2018-002880-25 ( EudraCT Number ) U1111-1210-0018 ( Registry Identifier: ICTRP ) |
First Posted: | November 27, 2018 Key Record Dates |
Last Update Posted: | December 14, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases |
Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn |